Anti-Depressant Drugs - Global Market Insights, Competitive Landscape, and Market Forecast - 2028

Anti-Depressant Drugs - Global Market Insights, Competitive Landscape, and Market Forecast - 2028

Anti-Depressant Drugs Market By Drug Type (Selective Serotonin Reuptake Inhibitors (SSRI), Selective-Norepinephrine Reuptake Inhibitors (SNRI), Tricyclic Antidepressants (TCA), Monoamine Oxidase Inhibitors (MAOI), And Others), Application (Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), General Anxiety Disorder (GAD), Panic Disorder (PD), And Others), and geography is expected to grow at a steady CAGR forecast till 2028 owing to increasing number of people with depression and increasing research and development activities

The global anti-depressant drugs market was valued at USD XX million in 2022, growing at a CAGR of XX% during the forecast period from 2023 to 2028 to reach USD XX million by 2028. The demand for anti-depressant drugs is primarily being boosted by the increasing number of cases of depression around the world coupled with increasing awareness about depression. Furthermore, the anti-depressant drugs market is anticipated to grow on account of a large number of ongoing research activities in this field, collaborations between healthcare providers, researchers, and industry players, and strategic partnerships among others are going to contribute to the overall growth of the anti-depressant drugs market during the forecast period from 2023-2028.

Anti-Depressant Drugs Market Dynamics:

The continuous rise in cases of psychiatric comorbidities such as depression, obsessive-compulsive disorder, and others is driving the growth of the anti-depressant drugs market. As per the data published by the World Health Organization (WHO) in 2022, worldwide around 970 million people which makes 1 in every 8 people were living with a mental disorder in 2019. The source further stated that anxiety and depressive disorders with anxiety affecting 301 million people including 58 million children and adolescents were the most common mental disorders in 2019 globally.

As per the above-mentioned source worldwide around 280 million people making up 3.8% of the global population including 23 million children and adolescents were suffering from depression in 2019.

Similarly, ongoing research activities about the development of novel anti-depressant drugs will accelerate market growth in the foreseeable future. For example, in November 2022, Autobahn Therapeutics announced the initiation of a Phase I clinical trial of ABX-002 intended for the treatment of major depressive disorder.

However, regulatory compliance and other safety concerns associated with anti-depressant drugs along with social stigma, discrimination, and other challenges encountered by people with mental health conditions may restrict the growth of the overall anti-depressant drugs market.

Anti-Depressant Drugs Market Segment Analysis:

Anti-Depressant Drugs Market by Drug Type (Selective Serotonin Reuptake Inhibitors (SSRI), Selective-Norepinephrine Reuptake Inhibitors (SNRI), Tricyclic Antidepressants (TCA), Monoamine Oxidase Inhibitors (MAOI), and Others), Application (Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), General Anxiety Disorder (GAD), Panic Disorder (PD), and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the application segment of the Anti-Depressant Drugs market, the Selective-Norepinephrine Reuptake Inhibitor (SNRI), category is expected to amass a significant revenue share in the year 2022. This can be ascribed to the surge in cases of depression and anxiety disorders and the role of Selective-Norepinephrine Reuptake Inhibitors (SNRI) in their treatment and management.

Serotonin is referred to as the ""feel-good hormone"" as it facilitates communication between brain cells and supports social behavior, appetite, mood, and overall well-being. It also aids in the regulation of the body's internal clock and sleep-wake cycle.

Another neurotransmitter that is believed to play a role in the control of emotions and mental processes is norepinephrine.

By preventing or postponing the absorption of serotonin and norepinephrine by nerves, selective serotonin-norepinephrine reuptake inhibitors, or SSNRIs, raise serotonin and norepinephrine levels in the brain.

SNRIs assist in easing the depressed symptoms associated with major depressive disorder (MDD), including irritability, poor mood, anxiety, restlessness, and difficulties falling asleep.

For example, Desvenlafaxine, belonging to a class of serotonin-norepinephrine reuptake inhibitor class is a medication used to treat depression.

The expanding applications of SNRIs in the treatment of abnormal psychological changes with improved efficacy are going to increase the demand for the same.

Therefore, owing to the above-mentioned factors, the Selective-Norepinephrine Reuptake Inhibitors (SNRI) category is expected to register significant growth, thereby driving the growth of the overall anti-depressant drugs market during the forecast period.

North America is expected to dominate the overall Anti-Depressant Drugs Market:

Among all the regions, North America is estimated to account for the largest share of the anti-depressant drugs market in the year 2022. Owing to the significance of key growth factors such as the rising prevalence of neurological disorders, increasing cases of psychiatric disorders, high disposable income, sophisticated healthcare infrastructure, presence of key players, increasing product development activities, and others, the market for anti-depressant drugs is expected to witness prosperity in the region during the forecast period 2022-2028.

According to the National Institute of Mental Health (NIMH) 2022, about 52.9 million people which stands for 21% of the population experienced mental illness in 2020 in the United States. As per the same source 14.2 million people experienced serious mental illness in the United States in 2020.

The above-mentioned source further stated that around 21.0 million adults had at least one major depressive episode in 2020 in the United States.

Coupled with the factors mentioned above, the increasing number of product development activities in the region are also going to assist in the market growth of anti-depressant drugs. For example, in September 2023, The US Food and Drug Administration (FDA) approved a new drug Exxua by Fabre-Kramer Pharmaceuticals to treat major depressive disorder in adults. The drug does not have common side effects found with other drugs for depression.

Thus, the above-mentioned factors are likely to propel the growth of the anti-depressant drugs market in the region during the forecast period from 2023-2028.

Anti-Depressant Drugs Market Key Players:

Some of the key market players operating in the anti-depressant drugs market include AbbVie Inc., AstraZeneca, Eli Lilly and Company, GlaxoSmithKline PLC, H. Lundbeck AS, Johnson & Johnson, Pfizer Inc., Organon group of companies, Takeda Pharmaceutical Company Limited, Novartis AG, Biogen Inc., Sage Therapeutics, Axsome Therapeutics, Fabre-Kramer Pharmaceuticals, Inc., Lupin, Teva Pharmaceutical Industries Ltd., Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Dr Reddy’s Laboratories Ltd., and Others.

Recent Developmental Activities in the Anti-Depressant Drugs Market:

In August 2023, Biogen Inc. and Sage Therapeutics, Inc. announced that the US Food and Drug Administration (FDA) has approved ZURZUVAE™ (zuranolone) 50 mg for adults with postpartum depression (PPD).

In August 2022, the US FDA approved Auvelity which is an extended-release dextromethorphan/bupropion tablet intended for the treatment of major depressive disorder in adults.

In August 2020, The Janssen Pharmaceutical Companies of Johnson & Johnson

announced that the US FDA has approved the supplemental new drug application (sNDA) for SPRAVATO® (esketamine) CIII nasal spray, taken with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.

Key Takeaways from the Anti-Depressant Drugs Market Report Study

Market size analysis for current anti-depressant drugs market size (2022), and market forecast for 5 years (2023-2028)

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global anti-depressant drugs market.

Various opportunities available for the other competitors in the anti-depressant drugs market space.

What are the top-performing segments in 2022? How these segments will perform in 2028?

Which are the top-performing regions and countries in the current anti-depressant drugs market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for anti-depressant drugs market growth in the coming future?

Target Audience who can be benefited from this Anti-Depressant Drugs Market Report Study

Anti-depressant drug product providers

Research organizations and consulting companies

Anti-Depressant Drugs -related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in anti-depressant drugs

Various End-users who want to know more about the anti-depressant drugs market and the latest developments in the anti-depressant drugs market.

Frequently Asked Questions for the Anti-Depressant Drugs Market:

1. What are anti-depressant drugs?

Anti-depressant drugs are prescription medicines that are used to treat clinical depression or prevent it from recurring.

2. What is the market for global anti-depressant drugs?

The global Anti-Depressant Drugs market was valued at USD XX million in 2022, growing at a CAGR of XX% during the forecast period from 2023 to 2028 to reach USD XX million by 2028.

3. What are the drivers for the global anti-depressant drugs market?

The demand for anti-depressant drugs is primarily being boosted by the increasing number of cases of depression around the world coupled with increasing awareness about depression. Furthermore, the anti-depressant drugs market is anticipated to grow on account of a large number of ongoing research activities in this field, collaborations between healthcare providers, researchers, and industry players, and strategic partnerships among others are going to contribute to the overall growth of the anti-depressant drugs market during the forecast period from 2023-2028.

4. Who are the key players operating in the global anti-depressant drugs market?

Some of the key market players operating in the anti-depressant drugs market include AbbVie Inc., AstraZeneca, Eli Lilly and Company, GlaxoSmithKline PLC, H. Lundbeck AS, Johnson & Johnson, Pfizer Inc., Organon group of companies, Takeda Pharmaceutical Company Limited, Novartis AG, Biogen Inc., Sage Therapeutics, Axsome Therapeutics, Fabre-Kramer Pharmaceuticals, Inc., Lupin, Teva Pharmaceutical Industries Ltd., Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Dr Reddy’s Laboratories Ltd., and Others.

5. Which region has the highest share in the anti-depressant drugs market?

North America is expected to dominate the overall anti-depressant drugs market during the forecast period from 2023-2028. Owing to factors such as the rise in the number of people with anxiety and depressive disorders, the surge in the number of awareness programs and initiatives for mental health, high disposable income, sophisticated healthcare infrastructure, and surge in product development activities among others, North American Anti-Depressant Drugs market is expected to growth in coming years.

Please Note: It will take 3-5 business days to complete the report upon order confirmation.